Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jian-Xin Lin

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Biorxiv : the Preprint Server for Biology|May 19, 2023
Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activityElissa K Leonard, Jakub Tomala, Joseph R Gould, et al.
Frontiers in Immunology|August 15, 2022
Investigation of the causal etiology in a patient with T-B+NK+ immunodeficiencyRobert Sertori, Jian-Xin Lin, Esteban Martinez, et al.
The Journal of Clinical Investigation|April 15, 2021
Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation toleranceToshihito Hirai, Teresa L Ramos, Po-Yu Lin, et al.
Nature Immunology|March 8, 2016
A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-betAnnie Xin, Frederick Masson, Yang Liao, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2020
Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8<sup>+</sup> T cell stemness and antitumor immunityDalton Hermans, Sanjivan Gautam, Juan C García-Cañaveras, et al.
JCI Insight|August 8, 2024
Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activityElissa K Leonard, Jakub Tomala, Joseph R Gould, et al.
Science Immunology|November 3, 2023
Distinct use of super-enhancer elements controls cell type-specific CD25 transcription and functionRosanne Spolski, Peng Li, Vivek Chandra, et al.
Nature|September 16, 2021
An engineered IL-2 partial agonist promotes CD8<sup>+</sup> T cell stemnessFei Mo, Zhiya Yu, Peng Li, et al.
Nature|June 8, 2022
Potentiating adoptive cell therapy using synthetic IL-9 receptorsAnusha Kalbasi, Mikko Siurala, Leon L Su, et al.
Nature|May 14, 2025
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunityJiajia Zhou, Kole Tison, Haibin Zhou, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Biorxiv : the Preprint Server for Biology|May 19, 2023
Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activityElissa K Leonard, Jakub Tomala, Joseph R Gould, et al.
Frontiers in Immunology|August 15, 2022
Investigation of the causal etiology in a patient with T-B+NK+ immunodeficiencyRobert Sertori, Jian-Xin Lin, Esteban Martinez, et al.
The Journal of Clinical Investigation|April 15, 2021
Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation toleranceToshihito Hirai, Teresa L Ramos, Po-Yu Lin, et al.
Nature Immunology|March 8, 2016
A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-betAnnie Xin, Frederick Masson, Yang Liao, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2020
Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8<sup>+</sup> T cell stemness and antitumor immunityDalton Hermans, Sanjivan Gautam, Juan C García-Cañaveras, et al.
JCI Insight|August 8, 2024
Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activityElissa K Leonard, Jakub Tomala, Joseph R Gould, et al.
Science Immunology|November 3, 2023
Distinct use of super-enhancer elements controls cell type-specific CD25 transcription and functionRosanne Spolski, Peng Li, Vivek Chandra, et al.
Nature|September 16, 2021
An engineered IL-2 partial agonist promotes CD8<sup>+</sup> T cell stemnessFei Mo, Zhiya Yu, Peng Li, et al.
Nature|June 8, 2022
Potentiating adoptive cell therapy using synthetic IL-9 receptorsAnusha Kalbasi, Mikko Siurala, Leon L Su, et al.
Nature|May 14, 2025
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunityJiajia Zhou, Kole Tison, Haibin Zhou, et al.
Pageof 5